Journal of Pharmacy and Pharmaceutical Research Open Access

  • Journal h-index: 3
  • Journal CiteScore: 0.94
  • Journal Impact Factor: 0.52
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658

Jianghua Ding

Department of Hematology and Oncology, The Affiliated Hospital of Jiujiang University, China

  • Research Article   
    Anlotinib Maintenance Following Adjuvant Chemotherapy in Newly Diagnosed Stage III-IV Patients with Epithelial Ovarian Cancer: A Retrospective Study
    Author(s): Jianghua Ding*

    Background and Aims: Anti-angiogenesis therapy with bevacizumab maintenance marginally improved the median progression-free survival (mPFS) of 4.9 months in patients with advanced epithelial ovarian cancer (EOC). Anlotinib, an oral small-molecular anti-angiogenic agent, has been reported to treat platinum-resistant EOC. However, little is known about anlotinib maintenance therapy in newly diagnosed EOC. Methods: This retrospective study included 20 patients with newly diagnosed EOC from a single hospital between January 2020 and December 2021. The primary endpoints were mPFS, the overall response rate (ORR), and the Disease Control Rate (DCR). Adverse reactions to therapy were also assessed. Results: Among all EOC patients, the ORR was 65% (13/20) and the DCR was 95% (19/20), while the mPFS was 14.8 m.. View More»

    DOI: 10.21767/IPIPR.23.7.001

    Abstract HTML PDF